Liquid Biopsy Surveillance and Early Detection Summit

Conference themes
In the wake of new FDA guidance and exciting MRD partnership announcements between Grail and AstraZeneca, Amgen and Bristol Myers Squibb the liquid biopsy industry is experiencing a paradigm shift. Touted as having the potential to transform clinical practice as we know it, technical progress and mounting investment in premetastatic applications are creating huge industry-wide excitement for liquid biopsy-based screening and surveillance for novel precision drug development.

Professional congress organizer (PCO)
Hanson Wade

Notes
Brochure: https://go.evvnt.com/1315351-3?pid=4832

Speakers: Aadel Chaudhuri, Assistant Professor of Radiation Oncology, Washington University School of Medicine, and more.

https://go.evvnt.com/1315351-2?pid=4832

Mr. Alex Domingo